Suchergebnis | Hamburg Open Science

Facetten

2 Einträge gefunden

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)
2021 - Forschungsinformationssystem des UKE - frei zugänglich
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
2020 - Forschungsinformationssystem des UKE